Table 1.
Summary of clinical and CMRI features of the 27 cases. LVEF_cmr: LVEF estimated by CMR; LVEDVI_cmr: LVEDVI estimated by CMR
| Case | No. of doses | Vaccine | Days from injection to presentation | Age | Sex | BMI | Autoimmunities | Fever (> 37.5 °C) | Chest pain | Palpitations | Myalgia | Dyspnea | Troponin (hs-cTnT/cTnl) level baseline | Troponin lab cutoff value | Elevated troponins | ECG baseline anomalies | CMR date | LVEF_cmr | LVEDVI_cmr | LGE | LGE segments (AHA) | LGE pattern | T1 mapping global | ECV_cmr | T2 mapping global | Pericarditis_cmr | FU days | At FU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 1 | Vaxzevria (AstraZeneca) | 19 | 20 | M | 24.07 | 0 | 0 | 1 | 0 | 0 | 0 | 593 | cTnT < 14 ng/L | 1 | 1 | 27/06/2021 | 47 | 89 | 1 | 11, 12, 16 | Mid-epicardial | 1026 | 26 | 48 | 0 | 44 | 0 |
| Case 2 | 1 | Comirnaty (Pfizer/BioNTech) | 1 | 43 | M | 25.95 | 0 | 0 | 1 | 1 | 1 | 0 | 706 | cTnT < 14 ng/L | 11 | 1 | 17/06/2021 | 50 | 73 | 1 | 5, 6, 11, 12, 13, 14, 15, 16 | Mid-epicardial | 1201 | 42 | 65 | 0 | 49 | 0 |
| Case 3 | 1 | Comirnaty (Pfizer/BioNTech) | 8 | 41 | F | 31.22 | 1 | 0 | 1 | 1 | 0 | 1 | 676 | cTnT < 14 ng/L | 1 | 1 | 21/05/2021 | 62 | 54 | 1 | 2, 3, 8, 9, 10 | Mid-epicardial | Not performed | Not performed | Not performed | 1 | 13 | 0 |
| Case 4 | 2 | Comirnaty (Pfizer/BioNTech) | 3 | 44 | M | 28.4 | 0 | 0 | 1 | 0 | 1 | 1 | 7400 | cTnT < 34.2 ng/L | 1 | 1 | 25/07/2021 | 69 | 67 | 1 | 4, 5, 10, 15 | Mid-epicardial | 1280 (3T) | 27 (3T) | 56 (3T) | 1 | 4 | 0 |
| Case 5 | 2 | Comirnaty (Pfizer/BioNTech) | 4 | 26 | M | 23.7 | 0 | 1 | 1 | 1 | 0 | 0 | 2500 | cTnT < 57 ng/L | 1 | 1 | 18/03/2021 | 70 | 90 | 1 | 4, 5, 6, 10, 11, 12, 15 | Mid-epicardial | Not performed | Not performed | Not performed | 0 | 82 | 0 |
| Case 6 | 2 | Comirnaty (Pfizer/BioNTech) | 9 | 41 | M | 27.6 | 0 | 1 | 1 | 1 | 0 | 0 | 5533 | cTnT < 57 ng/L | 1 | 1 | 05/08/2021 | 57 | 121 (dilated) | 1 | 4, 5, 10, 11, 16 | Mid-epicardial | 1075 | 33 | 53 | 1 | 6 | 0 |
| Case 7 | 2 | Spikevax (Moderna) | 6 | 27 | M | 22.5 | 0 | 1 | 1 | 0 | 1 | 0 | 119 | cTnT < 14 ng/L | 1 | 0 | 15/06/2021 | 60 | 94 | 1 | 1, 4 | Mid-epicardial | Not performed | Not performed | Not performed | 0 | 4 | 0 |
| Case 8 | 1 | Spikevax (Moderna) | 1 | 57 | M | 23.63 | 0 | 1 | 1 | 0 | 0 | 0 | 715 | cTnT < 14 ng/L | 1 | 0 | 17/06/2021 | 70 | 76 | 1 | 6, 5, 11, 12 | Mid-wall | Not performed | Not performed | Not performed | 0 | 35 | 0 |
| Case 9 | 1 | Comirnaty (Pfizer/BioNTech) | 2 | 12 | M | 17.2 | 0 | 0 | 1 | 0 | 0 | 0 | 695 | cTnT < 14 ng/L | 1 | 1 | 14/07/2021 | 80 | 95 | 0 | Pericardial | 980 | 25 | 51 | 1 | 2 | 0 | |
| Case 10 | 1 | Comirnaty (Pfizer/BioNTech) | 6 | 20 | M | 20.43 | 0 | 0 | 1 | 0 | 0 | 0 | 1406 | cTnT < 14 ng/L | 1 | 0 | 07/07/2021 | 58 | 93.4 | 1 | 6 | Mid-epicardial | Not performed | Not performed | Not performed | 0 | 25 | 0 |
| Case 11 | 2 | Comirnaty (Pfizer/BioNTech) | 14 | 18 | M | 22.09 | 0 | 1 | 1 | 0 | 0 | 0 | 427 | cTnT < 14 ng/L | 1 | 1 | 18/06/2021 | 62 | 63 | 1 | 7 | Mid-epicardial | 1076 | 29 | 54 | 0 | 43 | 0 |
| Case 12 | 1 | Comirnaty (Pfizer/BioNTech) | 3 | 33 | M | 28.3 | 0 | 1 | 1 | 0 | 0 | 0 | 27 | cTnT < 19,8 ng/L | 1 | 1 | 01/04/2021 | 54 | 84 | 1 | 3, 4, 13, 16 | Mid-epicardial | 1110 | Not performed | 58 | 0 | 30 | 0 |
| Case 13 | 2 | Vaxzevria (AstraZeneca) | 7 | 26 | M | 41.5 | 0 | 0 | 1 | 0 | 0 | 0 | 2500 | cTnT < 14 ng/L | 1 | 0 | 16/06/2021 | 56 | 89.7 | 1 | 2, 3, 4, 5, 8, 9, 10, 11 | Epicardial | 1157 | 35 | 47 | 0 | Unknown | Unknown |
| Case 14 | 2 | Vaxzevria (AstraZeneca) | 6 | 21 | M | 32 | 0 | 1 | 1 | 1 | 0 | 1 | 657 | cTnT < 14 ng/L | 1 | 1 | 23/06/2021 | 58 | 83 | 1 | 4, 5, 6, 11, 12 | Epicardial | 961 | 28 | 46 | 0 | Unknown | Unknown |
| Case 15 | 1 | Spikevax (Moderna) | 2 | 49 | M | 24.62 | 1 | 0 | 1 | 0 | 0 | 0 | 524 | cTnT < 14 ng/L | 1 | 1 | 18/05/2021 | 65 | 50 | 0 | 1045 | Not performed | 61 | 0 | 70 | 0 | ||
| Case 16 | 2 | Comirnaty (Pfizer/BioNTech) | 3 | 57 | M | 25.6 | 0 | 0 | 1 | 0 | 0 | 1 | 218 | cTnT < 14 ng/L | 1 | 1 | 21/06/2021 | 59 | 95.2 | 0 | 1037 | 25.32 | 50 | 1 | 26 | 0 | ||
| Case 17 | 2 | Comirnaty (Pfizer/BioNTech) | 7 | 26 | M | 27.4 | 0 | 0 | 1 | 1 | 0 | 0 | 382 | cTnT < 14 ng/L | 1 | 1 | 30/06/2021 | 61 | 81.3 | 0 | 987 | 24.28 | 48 | 1 | 9 | 0 | ||
| Case 18 | 2 | Comirnaty (Pfizer/BioNTech) | 5 | 55 | M | 33.8 | 0 | 1 | 1 | 1 | 1 | 1 | 1790 | cTnT < 14 ng/L | 1 | 1 | 07/07/2021 | 64 | 60.9 | 1 | 10, 11, 15, 16 | Mid-epicardial | 1043 | 25.61 | 48 | 0 | 14 | 0 |
| Case 19 | 2 | Spikevax (Moderna) | 4 | 29 | M | 28.1 | 0 | 1 | 1 | 0 | 1 | 0 | 516 | cTnT < 14 ng/L | 1 | 1 | 23/07/2021 | 52 | 76.8 | 1 | 4, 5, 10, 11, 12, 15, 16, 17 | Mid-epicardial | 1021 | 31.13 | 55 | 0 | 25 | 0 |
| Case 20 | 2 | Comirnaty (Pfizer/BioNTech) | 3 | 51 | M | 26.22 | 0 | 1 | 1 | 0 | 0 | 0 | 270 | cTnT < 14 ng/L | 1 | 1 | 10/07/2021 | 61 | 67 | 1 | 5 | Mid-epicardial | 1022 | Not performed | 43 | 0 | 20 | 0 |
| Case 21 | 2 | Comirnaty (Pfizer/BioNTech) | 2 | 31 | M | 23.67 | 0 | 1 | 1 | 0 | 0 | 0 | 378 | cTnT < 14 ng/L | 1 | 1 | 25/05/2021 | 75 | 79 | 1 | 3 | Mid-epicardial | 1030 | Not performed | 38 | 0 | 62 | 0 |
| Case 22 | 1 | Comirnaty (Pfizer/BioNTech) | 10 | 32 | M | 21.39 | 0 | 1 | 1 | 1 | 1 | 0 | 639 | cTnT < 14 ng/L | 1 | 1 | 14/07/2021 | 61 | 75 | 1 | 8 | Mid-epicardial | 1075 | Not performed | 59 | 0 | 15 | 0 |
| Case 23 | 1 | Comirnaty (Pfizer/BioNTech) | 23 | 19 | M | 24.62 | 0 | 1 | 1 | 1 | 1 | 0 | 587 | cTnT < 14 ng/L | 1 | 0 | 19/07/2021 | 49 | 88 | 1 | 5 | Mid-epicardial | 1010 | Not performed | 54 | 0 | 13 | 0 |
| Case 24 | 1 | Spikevax (Moderna) | 4 | 20 | M | 20.76 | 0 | 0 | 1 | 0 | 0 | 1 | 1494 | cTnT < 14 ng/L | 1 | 1 | 14/07/2021 | 62 | 86 | 1 | 10, 11, 15, 16 | Mid-epicardial | Not performed | Not performed | Not performed | 0 | 18 | 0 |
| Case 25 | 1 | Comirnaty (Pfizer/BioNTech) | 4 | 44 | M | 24 | 0 | 1 | 0 | 0 | 0 | 0 | 216 | cTnT < 34.2 ng/L | 1 | 1 | 14/07/2021 | 59 | 89.8 | 1 | 4.5 | Mid-wall | 1020 | 27 | 52 | 1 | 6 | 0 |
| Case 26 | 2 | Spikevax (Moderna) | 46 | 66 | F | 26 | 0 | 1 | 1 | 1 | 1 | 0 | 4209 | cTnT < 14 ng/L | 1 | 1 | 28/07/2021 | 51 | 73 | 1 | 4, 5, 10, 11 | Mid-epicardial | 1175 | 38 | 62 | 0 | 14 | 0 |
| Case 27 | 2 | Comirnaty (Pfizer/BioNTech) | 20 | 80 | M | 26.4 | 1 | 1 | 0 | 0 | 1 | 1 | 562 | cTnT < 14 ng/L | 1 | 0 | 15/06/2021 | 62 | 111 (dilated) | 1 | 3 | Mid-wall | 1060 | 31 | 55 | 0 | 76 | 0 |
| Mean | 8.222222222 | 36.5926 | 25.96926 | 0.111111111 | 0.592592593 | 0.92592593 | 0.37037037 | 0.33333333 | 0.25925926 | 1 | 0.777777778 | 60.5185185 | 78.924 | 0.851852 | 1055.55 | 30.02428571 | 52.35 | 0.259259259 | Median = 20 | 0 | ||||||||
| Standard deviation | 9.540735874 | 16.8163 | 4.792807 | 0.320256308 | 0.500711744 | 0.26688026 | 0.492102878 | 0.48038446 | 0.44657608 | 0 | 0.423659273 | 7.75772751 | 12.93980551 | 0.362014 | 63.66811563 | 5.357679914 | 6.690724137 | 0.446576085 | Range = 2-82 | 0 | ||||||||
1 = true ; 0 = false